Levetiracetam induced psoriasiform drug eruption: a rare case report

Gençler, Onur Serdar; Gençler, Bilgen; Altunel, Cemile Tuğba; Arslan, Nur

doi:10.1016/j.jsps.2015.02.010

Cited by 7 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cohen [19] Reticular eruption NR NR Unni et al, [27] Morbilliform rash that was erythematous, edematous with scaling and tiny pustules over the face and trunk NR Leucocytosis, eosinophilia Castro and Jafri [28] Exfoliative rash Worsening mental status Worsening transaminitis, direct hyperbilirubinaemia, changes in CT, leucocytosis, eosinophilia Panda [29] Pruritic maculopapular rash over the limbs and face with desquamation of skin over groin folds NR NR Gencler et al, [30] Psoriasiform drug eruptions NR NR Mangal and Kumaran [31] Multiple well-defined dusky erythematous, annular and arciform urticarial wheals on the lower limbs NR NR Bora et al, [32] Pale, pinkish, macular erythema with unclear borders on the sides of the abdomen NR NR (continued on next page) the cutaneous reaction. Methylprednisolone and dexamethasone were most commonly administered anti-inflammatory drugs.…”

Section: Study Dermatologic Reactions Non-dermatological Rx Biochemical Abnormalitiesmentioning

confidence: 99%

Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies

Rashid¹,

Rajan²,

Chhabra

et al. 2020

Seizure

View full text Add to dashboard Cite

Recently, there have been an increased number of reports on levetiracetam (LEV) induced cutaneous adverse drug reactions (CADRs). We aimed to identify and critically evaluate all the descriptive studies on LEV induced-CADRs and to describe the possible clinical manifestations, management, and treatment outcomes of the condition. Methodology: PubMed and grey literature databases were searched from inception to June 2019 without any restriction. We also performed a bibliographic search for additional studies. Only descriptive studies on LEVinduced CADRs were included for our review. Study selection, data abstraction and quality assessment were performed by two contributors independently and disagreements were settled through consensus or through discussion with a third reviewer. Results: Data from 24 out of 88 studies, which included 25 patients (12 female and 13 male) aged from 40 weeks to 73 years, were reviewed. Patients received between 500 mg/day to 3000 mg/day of LEV. Drug reaction with eosinophilia and systemic symptoms syndrome, Steven-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, generalised hyperpigmentation and leucocytoclastic vasculitis were observed among the included patients. Immediate cessation of LEV, providing supportive care and use of topical antihistamines and anti-inflammatory drugs appeared to be the mainstay of management, and all patients were found to have recovered. Conclusion:Clinicians should be aware of the possible CADRs induced by LEV to avoid the development of a potentially fatal condition. Immediate withdrawal of the drug and supporting care seem to be effective in the management of the CADRs. Registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42019141002.

show abstract

Section: Study Dermatologic Reactions Non-dermatological Rx Biochemical Abnormalitiesmentioning

confidence: 99%

Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies

Rashid¹,

Rajan²,

Chhabra

et al. 2020

Seizure

View full text Add to dashboard Cite

show abstract

“…The difference is the less erythema and scaling of psoriasiform lesions and sparing of knees and elbows than true psoriasis. 17 HCQ is also a well-known triggering factor in psoriasis flare-ups. The underlying mechanism contributing to this condition is the inhibitory effect of HCQ on epidermal trans-glutaminase, leading to the epidermal cells collection and its promotion effects on interleukin-17 (IL-17) production resulting in the overgrowth of keratinocytes.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, they may be mentioned as psoriasiform. The difference is the less erythema and scaling of psoriasiform lesions and sparing of knees and elbows than true psoriasis 17 . HCQ is also a well‐known triggering factor in psoriasis flare‐ups.…”

Section: Discussionmentioning

confidence: 99%

Pustular psoriasis flare‐up in a patient with COVID‐19

Miladi

Janbakhsh

Babazadeh

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1 has influenced a significant impact on public health, with approximately 175 million confirmed cases and more than 3 million deaths worldwide as of June 12, 2021. 2 Predominant pulmonary characteristics are the hallmark of this infection. Extrapulmonary symptoms have been reported worldwide in patients with COVID-19, including cardiovascular, 3 central nervous system (CNS), 4 renal, 5 gastrointestinal, 6 and hematologic manifestations. 7 In addition, various cutaneous manifestations have lately appeared in the setting of COVID-19 due to adverse effects of medications or increased immune response, one of which is the psoriasis flare-up. 8,27 Here, we present an unusual case of pustular psoriasis in a 32-year-old woman with a newly diagnosed COVID-19 infection.

show abstract

“…2 A psoriasiform eruption, as observed in our patient, is an entity that can clinically and/or histologically simulate psoriasis, noting that, in psoriasiform eruptions, the perivascular and interstitial infiltrate of eosinophils in the upper dermis is more frequent. 3 It can be induced by several drugs such as beta-blockers, antimalarial drugs, TNF inhibitors, interferon, growth factors, lithium, some antibiotics, antihypertensives and antiepileptic drugs, nonsteroidal antiinflammatory drugs, and terbinafine. 4 The time of onset is variable, and the discontinuation of the responsible drug depends on the severity of the disease.…”

mentioning

confidence: 99%

Cisplatin‐induced psoriasiform eruption

Ali

Belcadi

Ouarith

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Cisplatin is one of the most potential and widely used drugs for the treatment of various solid cancers such as testicular, ovarian, head and neck, bladder, lung, cervical cancer, melanoma, lymphomas, and several others. 1 Multiple cutaneous adverse effects have been reported with this molecule, such as skin rashes or nail changes.To date, we have not found a documented case of psoriasiform eruption due to cisplatin. Here, we report the observation of a psoriasiform eruption in an adult patient who received a cure of cisplatin.A 76-year-old patient, with a history of chronic heavy smoking, was treated for small cell lung cancer with cisplatin ( 40mg/m 2 ) and etoposide-based chemotherapy without growth factors nor concomitant radiotherapy. Four days after the first cure, he develops a pruritic rash. Clinical examination revealed erythematous plaques with hyperkeratotic scales on the trunk, back, four extremities, and periorbital area. (Figure 1A, B).No nail changes were noted.

show abstract

Levetiracetam induced psoriasiform drug eruption: a rare case report

Cited by 7 publications

References 13 publications

Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies

Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies

Pustular psoriasis flare‐up in a patient with COVID‐19

Cisplatin‐induced psoriasiform eruption

Contact Info

Product

Resources

About